Interpreting success or failure of peanut oral immunotherapy

Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. I...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 132; no. 2
Main Authors Cao, Shijie, Nagler, Cathryn R.
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 18.01.2022
Subjects
Online AccessGet full text

Cover

Loading…